Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in The Netherlands

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 313-317

  Hoogveldt, Bart ^a   Rive, Benoît ^b   Severens, Johan ^c   Maman, Khaled ^d   Guilhaume, Chantal ^e  

^a Field Product Management   (Netherlands)

^b Lundbeck   (France)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Creativ Research   (France)

^e SANOFI   (France)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cost effectiveness analysis; Memantine; Netherlands

Indexed keywords

MEMANTINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MONOTHERAPY; NETHERLANDS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

EID: 80053629389     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S19239     Document Type: Article

References (17)

1. Perenboom RJ, Boshuizen HC, Breteler MM, Ott A, Van de Water HP. Dementia-free life expectancy (DemFLE) in The Netherlands. Soc Sci Med. 1996;43:1703-1707.
2. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14:84-89.
3. McDonnell J, Redekop WK, Van der Roer N, et al. The cost of treatment of Alzheimer's disease in The Netherlands: A regression-based simulation model. Pharmacoeconomics. 2001;19:379-390.
4. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52:519-526.
5. College voor Zorgverzekeringen. Guidelines for Pharmacoeconomic Research, Updated Version. Diemen, The Netherlands: College voor Zorgverzekeringen; 2006.
6. Breteler MM. A community-based study of dementia: The Rotterdam Elderly Study. Neuroepidemiology. 1992;11 Suppl 1:S23-S28.
7. Ott A, Breteler M, Van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study. BMJ. 1995;310:970-973.
8. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
9. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized controlled trial. Am J Geriatr Psychiatry. 2006;14:704-715.
10. Bakchine S, Pascual-Gangnant L, Loft H. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Abstract presented at the Ninth Congress of the European Federation of the Neurological Societies (EFNS), September 17-20, 2005, Athens, Greece.
11. Van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderateto- severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21: 136-143.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49-54.
13. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor Kostenonderzoek. Amstelveen, The Netherlands: College voor Zorgverzekeringen; 2000.
14. Van der Roer N. Model of costs of care for dementia: communitydwelling vs institutionalization. Tijdschr Gerontol Geriatr. 2000;31: 55-61. Dutch.
15. Sapin C, Livingston G, Katona C. Main factors influencing preferencebased utility values in Alzheimer's disease: Results from the LASER-AD Study. Poster presented at the Seventh International Conference on Alzheimer's and Parkinson's Disease (AD/PD), March 9-13, 2005, Sorrento, Italy.
16. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409-418.
17. Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging. 2004;21:677-686.